Does Rallies track congressional trades in JNJ?

Yes. Rallies tracks politician and congressional stock disclosures for JNJ, including reported purchases, sales, dates, owners, and trade amounts when available.

Is JNJ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.

JNJ (Johnson & Johnson) Stock Analysis - Politician Trades

Johnson & Johnson (JNJ) is a publicly traded Healthcare sector company. As of May 20, 2026, JNJ trades at $230.00 with a market cap of $551.06B and a P/E ratio of 26.42. JNJ moved -0.35% today. Year to date, JNJ is +10.92%; over the trailing twelve months it is +50.83%. Its 52-week range spans $140.68 to $251.71. Analyst consensus is buy with an average price target of $264.75. Rallies surfaces JNJ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded JNJ stock?

Recent politician trading activity in JNJ includes disclosures from Thomas H. Kean, John Boozman, Ro Khanna, Thomas H. Kean, and Julie Johnson. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

JNJ Key Metrics

Key financial metrics for JNJ
Metric	Value
Price	$230.00
Market Cap	$551.06B
P/E Ratio	26.42
EPS	$8.73
Dividend Yield	1.34%
52-Week High	$251.71
52-Week Low	$140.68
Volume	3.37M
Avg Volume	0
Revenue (TTM)	$96.36B
Net Income	$21.04B
Gross Margin	67.82%

Congressional Trades in JNJ

Thomas H. Kean sale JNJ on Mar 26, 2026 (amount: $15.00K).
John Boozman sale JNJ on Mar 19, 2026 (amount: $15.00K) for Joint.
Ro Khanna purchase JNJ on Mar 6, 2026 (amount: $15.00K).
Thomas H. Kean sale JNJ on Jan 23, 2026 (amount: $50.00K).
Julie Johnson sale JNJ on Dec 18, 2025 (amount: $15.00K) for Joint.

Latest JNJ News

Johnson & Johnson Reports Darzalex, Tremfya Growth with AAA Rating, 64-Year Dividend Streak — May 19, 2026
Nanoradioenhancer JNJ-1900 Posts 85.7% Response Rate; Ebola Emergency Declared — May 17, 2026
Johnson & Johnson Stock Falls 3.5% as Survey Finds Over 90% of Bladder Cancer Patients Report Severe Impacts — May 14, 2026
JNJ jumps as Leerink upgrades to Outperform and lifts target to $265 — May 13, 2026
Johnson & Johnson Secures AAA Rating, One of Only Two U.S. Firms — May 13, 2026

Recent JNJ Insider Trades

Decker Robert J sold 4.08K (~$1.01M) on Feb 27, 2026.
Schmid Timothy sold 1.32K (~$324.76K) on Feb 20, 2026.
Schmid Timothy sold 13.63K (~$3.33M) on Feb 18, 2026.

JNJ Analyst Consensus

18 analysts cover JNJ: 0 strong buy, 12 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.75.

Common questions about JNJ

Which politicians traded JNJ stock?: Recent politician trading activity in JNJ includes disclosures from Thomas H. Kean, John Boozman, Ro Khanna, Thomas H. Kean, and Julie Johnson. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in JNJ?: Yes. Rallies tracks politician and congressional stock disclosures for JNJ, including reported purchases, sales, dates, owners, and trade amounts when available.
Is JNJ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.